Literature DB >> 27193555

Transforming growth factor-β and stem cell markers are highly expressed around necrotic areas in glioblastoma.

Yasuo Iwadate1, Tomoo Matsutani2, Seiichiro Hirono2, Natsuki Shinozaki2, Naokatsu Saeki2.   

Abstract

Invasion into surrounding normal brain and resistance to genotoxic therapies are the main devastating aspects of glioblastoma (GBM). These biological features may be associated with the stem cell phenotype, which can be induced through a dedifferentiation process known as epithelial-mesenchymal transition (EMT). We show here that tumor cells around pseudopalisading necrotic areas in human GBM tissues highly express the most important EMT inducer, transforming growth factor (TGF-β), concurrently with the EMT-related transcriptional factor, TWIST. In addition, the stem cell markers CD133 and alkaline phosphatase (ALPL) were also highly expressed around necrotic foci in GBM tissues. The high expression of TGF-β around necrotic regions was significantly correlated with shorter progression-free survival and overall survival in patients with GBM. High expression of stem cell markers, ALPL, CD133, and CD44 was also correlated with poor outcomes. These results collectively support the hypothesis that tissue hypoxia induces the stem cell phenotype through TGF-β-related EMT and contributes to the poor outcome of GBM patients.

Entities:  

Keywords:  EMT; Epithelial-mesenchymal transition; Glioma; Hypoxia; Microenvironment; TGF-β

Mesh:

Substances:

Year:  2016        PMID: 27193555     DOI: 10.1007/s11060-016-2145-6

Source DB:  PubMed          Journal:  J Neurooncol        ISSN: 0167-594X            Impact factor:   4.130


  41 in total

Review 1.  Glioblastoma: pathology, molecular mechanisms and markers.

Authors:  Kenneth Aldape; Gelareh Zadeh; Sheila Mansouri; Guido Reifenberger; Andreas von Deimling
Journal:  Acta Neuropathol       Date:  2015-05-06       Impact factor: 17.088

Review 2.  Brain tumor stem cells: Molecular characteristics and their impact on therapy.

Authors:  David L Schonberg; Daniel Lubelski; Tyler E Miller; Jeremy N Rich
Journal:  Mol Aspects Med       Date:  2013-07-04

Review 3.  Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy.

Authors:  Rakesh K Jain
Journal:  Science       Date:  2005-01-07       Impact factor: 47.728

4.  High TGFbeta-Smad activity confers poor prognosis in glioma patients and promotes cell proliferation depending on the methylation of the PDGF-B gene.

Authors:  Alejandra Bruna; Rachel S Darken; Federico Rojo; Alberto Ocaña; Silvia Peñuelas; Alexandra Arias; Raquel Paris; Avelina Tortosa; Jaume Mora; Jose Baselga; Joan Seoane
Journal:  Cancer Cell       Date:  2007-02       Impact factor: 31.743

5.  Hypoxia is important in the biology and aggression of human glial brain tumors.

Authors:  Sydney M Evans; Kevin D Judy; Isolde Dunphy; W Timothy Jenkins; Wei-Ting Hwang; Peter T Nelson; Robert A Lustig; Kevin Jenkins; Deirdre P Magarelli; Stephen M Hahn; Ruth A Collins; M Sean Grady; Cameron J Koch
Journal:  Clin Cancer Res       Date:  2004-12-15       Impact factor: 12.531

6.  The hypoxic microenvironment maintains glioblastoma stem cells and promotes reprogramming towards a cancer stem cell phenotype.

Authors:  John M Heddleston; Zhizhong Li; Roger E McLendon; Anita B Hjelmeland; Jeremy N Rich
Journal:  Cell Cycle       Date:  2009-10-03       Impact factor: 4.534

Review 7.  Targeting role of glioma stem cells for glioblastoma multiforme.

Authors:  X Zhang; W Zhang; X G Mao; H N Zhen; W D Cao; S J Hu
Journal:  Curr Med Chem       Date:  2013       Impact factor: 4.530

8.  Induction of DNA hypomethylation by tumor hypoxia.

Authors:  Siranoush Shahrzad; Kelsey Bertrand; Kanwal Minhas; Brenda L Coomber
Journal:  Epigenetics       Date:  2007-06-14       Impact factor: 4.528

Review 9.  The basics of epithelial-mesenchymal transition.

Authors:  Raghu Kalluri; Robert A Weinberg
Journal:  J Clin Invest       Date:  2009-06       Impact factor: 14.808

10.  Hypoxia-inducible factors regulate tumorigenic capacity of glioma stem cells.

Authors:  Zhizhong Li; Shideng Bao; Qiulian Wu; Hui Wang; Christine Eyler; Sith Sathornsumetee; Qing Shi; Yiting Cao; Justin Lathia; Roger E McLendon; Anita B Hjelmeland; Jeremy N Rich
Journal:  Cancer Cell       Date:  2009-06-02       Impact factor: 31.743

View more
  13 in total

1.  FHL3 links cell growth and self-renewal by modulating SOX4 in glioma.

Authors:  Wei Han; Peishan Hu; Fan Wu; Shanshan Wang; Yan Hu; Shanshan Li; Tao Jiang; Boqin Qiang; Xiaozhong Peng
Journal:  Cell Death Differ       Date:  2018-06-28       Impact factor: 15.828

Review 2.  Hypoxia in solid tumors: a key promoter of cancer stem cell (CSC) resistance.

Authors:  Masoud Najafi; Bagher Farhood; Keywan Mortezaee; Ebrahim Kharazinejad; Jamal Majidpoor; Reza Ahadi
Journal:  J Cancer Res Clin Oncol       Date:  2019-11-16       Impact factor: 4.553

Review 3.  Brain Cancer Stem Cells in Adults and Children: Cell Biology and Therapeutic Implications.

Authors:  Tamara J Abou-Antoun; James S Hale; Justin D Lathia; Stephen M Dombrowski
Journal:  Neurotherapeutics       Date:  2017-04       Impact factor: 7.620

4.  Paeoniflorin Inhibits Migration and Invasion of Human Glioblastoma Cells via Suppression Transforming Growth Factor β-Induced Epithelial-Mesenchymal Transition.

Authors:  Zhaotao Wang; Zhi Liu; Guoyong Yu; Xiaohu Nie; Weiqiang Jia; Ru-En Liu; Ruxiang Xu
Journal:  Neurochem Res       Date:  2018-02-08       Impact factor: 3.996

5.  Hallmarks of glioblastoma: a systematic review.

Authors:  Dorte Schou Nørøxe; Hans Skovgaard Poulsen; Ulrik Lassen
Journal:  ESMO Open       Date:  2017-02-22

6.  ELTD1 as a multi-focal target for malignant gliomas: preclinical studies.

Authors:  Michelle Zalles; Nataliya Smith; Debra Saunders; Mayra Guzman; Megan Lerner; Kar-Ming Fung; Anish Babu; James Battiste; Junho Chung; Kyusang Hwang; Junyeong Jin; Rheal A Towner
Journal:  Neurooncol Adv       Date:  2021-09-17

7.  Blocking epithelial-to-mesenchymal transition in glioblastoma with a sextet of repurposed drugs: the EIS regimen.

Authors:  Richard E Kast; Nicolas Skuli; Georg Karpel-Massler; Guido Frosina; Timothy Ryken; Marc-Eric Halatsch
Journal:  Oncotarget       Date:  2017-06-01

8.  Optimized monoclonal antibody treatment against ELTD1 for GBM in a G55 xenograft mouse model.

Authors:  Michelle Zalles; Nataliya Smith; Jadith Ziegler; Debra Saunders; Shannon Remerowski; Lincy Thomas; Rafal Gulej; Nadya Mamedova; Megan Lerner; Kar-Ming Fung; Junho Chung; Kyusang Hwang; Junyeong Jin; Graham Wiley; Chase Brown; James Battiste; Jonathan D Wren; Rheal A Towner
Journal:  J Cell Mol Med       Date:  2019-12-21       Impact factor: 5.310

Review 9.  Mesenchymal Transformation: The Rosetta Stone of Glioblastoma Pathogenesis and Therapy Resistance.

Authors:  Zulfikar Azam; Shing-Shun Tony To; Bakhos A Tannous
Journal:  Adv Sci (Weinh)       Date:  2020-09-28       Impact factor: 16.806

Review 10.  Postmortem brain donations vs premortem surgical resections for glioblastoma research: viewing the matter as a whole.

Authors:  Cassandra P Griffin; Christine L Paul; Kimberley L Alexander; Marjorie M Walker; Hubert Hondermarck; James Lynam
Journal:  Neurooncol Adv       Date:  2021-11-18
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.